| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Clinical |
Authors' Affiliations: Departments of 1 Medical Oncology, and 2 Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Division of Medical Oncology, Brigham and Women's Hospital; 3 Massachusetts General Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts; and 4 MGI Pharma Biologics, Lexington, Massachusetts
Requests for reprints: Lee M. Nadler, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. Phone: 617-632-4939; Fax: 617-632-3541; E-mail: lee_nadler{at}dfci.harvard.edu.
Purpose: The carcinogen activator cytochrome P450 1B1 (CYP1B1) is expressed on almost all human tumors with rare expression on normal tissues. Anti-CYP1B1–specific T cells kill CYP1B1-expressing tumors, providing the rationale to examine CYP1B1 as a target for immunotherapy.
Experimental Design: ZYC300, a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles, was used in a phase I clinical trial to treat 17 patients with advanced stage, progressive cancer. ZYC300 was administered i.m. at a fixed dose of 400 µg every other week for up to 12 doses.
Results: Thirteen patients received six vaccinations and five received all 12 doses. No significant adverse events were observed. Six patients developed immunity to CYP1B1, three of whom developed disease stabilization. All but 1 of 11 patients who did not develop immunity to CYP1B1 progressed and did not respond to salvage therapy. Five patients who developed immunity to CYP1B1 required salvage therapy for progressive metastatic disease and showed marked response to their next treatment regimen, most of which lasted longer than 1 year.
Conclusions: The association between immunity to CYP1B1 and response to next salvage therapy was not expected. Because six of the seven patients who had clinical benefit regardless of the nature of salvage therapy had developed immunity to CYP1B1, it seems highly unlikely that this occurred by chance alone. Regardless of the mechanism(s) that induced tumor regression, these findings force us to rethink how the generation of antitumor immunity might be integrated into the treatment of cancer.
Key Words: DNA vaccine • universal tumor antigen • immunotherapy
This article has been cited by other articles:
|
|
 |
|
  C. Menard, J.-Y. Blay, C. Borg, S. Michiels, F. Ghiringhelli, C. Robert, C. Nonn, N. Chaput, J. Taieb, N. F. Delahaye, et al. Natural Killer Cell IFN-{gamma} Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients Cancer Res., April 15, 2009; 69(8): 3563 - 3569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. SU, P. LIN, C.-K. WANG, and H. CHANG Overexpression of Cytochrome P450 1B1 in Advanced Non-small Cell Lung Cancer: A Potential Therapeutic Target Anticancer Res, February 1, 2009; 29(2): 509 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Cheever, J. Schlom, L. M. Weiner, H. K. Lyerly, M. L. Disis, A. Greenwood, O. Grad, W. G. Nelson, and for the Translational Research Working Group Translational Research Working Group Developmental Pathway for Immune Response Modifiers Clin. Cancer Res., September 15, 2008; 14(18): 5692 - 5699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Madan, J. L. Gulley, J. Schlom, S. M. Steinberg, D. J. Liewehr, W. L. Dahut, and P. M. Arlen Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy Clin. Cancer Res., July 15, 2008; 14(14): 4526 - 4531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Gulley, P. M. Arlen, K.-Y. Tsang, J. Yokokawa, C. Palena, D. J. Poole, C. Remondo, V. Cereda, J. L. Jones, M. P. Pazdur, et al. Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma Clin. Cancer Res., May 15, 2008; 14(10): 3060 - 3069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schlom, J. L. Gulley, and P. M. Arlen Paradigm Shifts in Cancer Vaccine Therapy Experimental Biology and Medicine, May 1, 2008; 233(5): 522 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schlom, P. M. Arlen, and J. L. Gulley Immunotherapies with Other Therapeutic Modalities: New Paradigms for Clinical Trial Design ASCO Educational Book, January 1, 2008; 2008(1): 101 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schlom, P. M. Arlen, and J. L. Gulley Cancer Vaccines: Moving Beyond Current Paradigms Clin. Cancer Res., July 1, 2007; 13(13): 3776 - 3782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Small, N. Sacks, J. Nemunaitis, W. J. Urba, E. Dula, A. S. Centeno, W. G. Nelson, D. Ando, C. Howard, F. Borellini, et al. Granulocyte Macrophage Colony-Stimulating Factor-Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer Clin. Cancer Res., July 1, 2007; 13(13): 3883 - 3891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Barnett, D. L. Urbauer, G. I. Murray, G. N. Fuller, and A. B. Heimberger Cytochrome P450 1B1 Expression in Glial Cell Tumors: An Immunotherapeutic Target Clin. Cancer Res., June 15, 2007; 13(12): 3559 - 3567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dessureault, D. Noyes, D. Lee, M. Dunn, W. Janssen, A. Cantor, E. Sotomayor, J. Messina, and S. J. Antonia A phase-I Trial Using a Universal GM-CSF-producing and CD40L-expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-based Vaccines for Cancer Patients with Stage IV disease Ann. Surg. Oncol., February 1, 2007; 14(2): 869 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Antonia, N. Mirza, I. Fricke, A. Chiappori, P. Thompson, N. Williams, G. Bepler, G. Simon, W. Janssen, J.-H. Lee, et al. Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer Clin. Cancer Res., February 1, 2006; 12(3): 878 - 887. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
